–
The U.S. Food and Drug Administration (FDA) approved an emergency use of a novel coronavirus infection (Corona 19) vaccine developed by Janssen, a subsidiary of pharmaceutical company Johnson & Johnson (J&J) on the 27th (local time).
According to the AP-AFP news agency on the 28th, the US FDA agreed to accept the recommendation to approve the emergency use of the Corona 19 vaccine developed by J&J subsidiary Janssen through a vote of the Vaccine and Biological Drugs Advisory Committee (VRBPAC) the day before did.
In general, FDA’s recommendation for emergency use approval has been regarded as an expert certification process for vaccine safety and efficacy.
VRBPAC unanimously recommended approval for urgent use of J&J’s Corona 19 vaccine (developed by Janssen) to adult Americans (over 18 years old).
The U.S. thus secured the third COVID-19 vaccine with the approval of the Janssen vaccine following the vaccine developed by Pfizer-Germany Bioentech and Modena.
However, the COVID-19 vaccine jointly developed by British pharmaceutical company AstraZeneca-Oxford University has not obtained FDA approval.
In particular, J&J’s Janssen vaccine is immunized with just one vaccination, unlike Pfizer, Moder, and vaccines that require a total of 2 vaccinations.
In addition, the existing vaccines have low immunity against the South African variant virus, whereas the Janssen vaccine has a high immunity effect against the variant virus.
Copyright © Shin-A Ilbo Unauthorized reproduction and redistribution prohibited
–
